Imperfect Information: Since Tumor Promotion By Prasugrel Was Unprovable, FDA Asked If It Was Biologically Plausible

In a setting of imperfect information regarding the hot-button issue of whether prasugrel has a tumor promotion effect, FDA put greater weight on the explanatory powers of modes of assessment that are normally overshadowed by clinical evaluation.